Clinical & Translational Oncology最新文献

{"title":"EGFR exon 20-altered NSCLC in China: molecular heterogeneity and real-world outcomes with sunvozertinib.","authors":"Jiahui Zhang, Yuechen Cui, Qing Ren, Xinyi Wu, Jingjing Li, Xin Liu, Bin Zhang, Dongsheng Yue","doi":"10.1007/s12094-026-04583-3","DOIUrl":"https://doi.org/10.1007/s12094-026-04583-3","url":null,"abstract":"<p><strong>Purpose: </strong>EGFR exon 20 alterations are uncommon and heterogeneous in non-small cell lung cancer (NSCLC), with reduced sensitivity to conventional EGFR tyrosine kinase inhibitors. This study aimed to characterize their molecular spectrum, clinical relevance, and real-world outcomes.</p><p><strong>Patients and methods: </strong>We retrospectively analyzed 50 patients with NSCLC harboring EGFR exon 20 alterations confirmed by next-generation sequencing. Mutation spectrum, structural distribution, co-occurring genomic alterations, clinicopathological features, treatment patterns, and overall survival (OS) were evaluated. Associations between molecular features, sunvozertinib exposure, and OS were assessed using Kaplan-Meier survival analysis and Firth penalized Cox regression.</p><p><strong>Results: </strong>EGFR exon 20 alterations showed marked molecular heterogeneity, with multiple mutation subtypes and structural subclasses. Co-occurring genomic alterations were frequent, and TP53 was the most common concomitant alteration. TP53 co-mutation was associated with inferior OS. Exploratory Kaplan-Meier analysis suggested shorter OS for far-loop than near-loop variants, although the subgroups were small and imbalanced. Among non-surgical patients, sunvozertinib exposure was associated with longer OS in unadjusted analysis, but this association did not remain statistically significant after multivariable adjustment.</p><p><strong>Conclusion: </strong>This study provides real-world evidence of the molecular and clinical heterogeneity of EGFR exon 20-altered NSCLC. TP53 co-mutation was associated with poorer OS. Exploratory analyses suggested a possible survival difference according to loop location and a potentially favorable association between sunvozertinib exposure and OS among non-surgical patients, although the adjusted results varied across models and were limited by the small number of survival events. These findings highlight the potential relevance of molecular stratification but require validation in larger prospective cohorts.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149118045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of the MDM2/p53 axis in regulating cisplatin response in tumor cells.","authors":"Yasamin Rajabloo, Iman Akhlaghipour, Negin Taghehchian, Meysam Moghbeli","doi":"10.1007/s12094-026-04389-3","DOIUrl":"10.1007/s12094-026-04389-3","url":null,"abstract":"<p><p>Cisplatin remains a cornerstone chemotherapeutic agent for a broad spectrum of solid malignancies; however, the emergence of intrinsic and acquired resistance severely limits its clinical efficacy. Central to the cellular decision between DNA damage repair and apoptosis following cisplatin exposure is the tumor suppressor p53, whose function is tightly governed by its primary negative regulator, Murine Double Minute 2 (MDM2). This review provides a critical synthesis of the molecular interplay within the MDM2/p53 axis and its direct impact on cisplatin sensitivity. We discussed how deregulation of this axis via TP53 mutational inactivation or MDM2 overexpression enables tumor cells to tolerate cisplatin-induced genotoxic stress. Specifically, we analyzed the dual role of MDM2: its E3 ubiquitin ligase activity that targets p53 for proteasomal degradation, and its emerging p53-independent functions in promoting DNA repair fidelity. Furthermore, we evaluated the therapeutic implications of targeting this pathway with small-molecule MDM2 antagonists. We assessed preclinical and clinical evidence supporting the use of MDM2 inhibition to lower the apoptotic threshold and re-sensitize resistant tumors to cisplatin. Therefore, an understanding of the MDM2/p53 feedback loop is essential for optimizing cisplatin-based regimens and developing rational combination therapies to circumvent chemoresistance.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"4597-4609"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147976941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evidence-steered medicine in oncology: network-aware micro-combinations that safeguard standard of care and potentially improve benefit-risk.","authors":"Konstantin Gurbanov","doi":"10.1007/s12094-026-04354-0","DOIUrl":"10.1007/s12094-026-04354-0","url":null,"abstract":"<p><p>Standard oncology regimens often follow a dose-optimization paradigm: intensify a single agent until efficacy emerges or toxicity intervenes. Yet many targets sit in compensatory tumor-host networks that reroute around pathway pressure, while incremental efficacy may plateau as dose rises and toxicity escalates. Clinical reality is further complicated by heterogeneous patient states, including suppressed antigen presentation (e.g., β2-microglobulin loss or antigen-processing/presentation machinery defects), immature or poorly trafficking dendritic cells, and symptom/toxicity burdens that drive dose delays or reductions and erode relative dose intensity. These factors contribute to late-stage monotherapy failures and leave clinicians with a binary choice-more of the same therapy or a complete stop-when the actionable question is often whether a small, precisely timed change could restore the preconditions under which standard-of-care (SoC) therapy works best. Evidence-steered medicine (ESM) proposes a conservative adjunctive framework that adds only tiny, single-pulse exposures (\"micro-adjuncts\") without delaying or displacing SoC. Each micro-adjunct is pre-specified with a directional mechanistic hypothesis and read out by short-horizon proxies at 48-96 h (e.g., HLA-ABC and TAP1/2 for antigen presentation; CD86/CCR7 for antigen-presenting-cell activation and trafficking readiness; hs-CRP for systemic inflammatory tone; HRV and symptom scores for host readiness). ESM enforces three safety-first gates: a mechanistic sign-consistency check; a transportability/overlap screen to avoid out-of-support exposure; and a banded decision rule that acts only when the pessimistic bound of the expected proxy effect exceeds a preset threshold under strict exposure caps, otherwise defaulting to NO-STEP. Governance features-drug-drug interaction matrices, order-set blocks, one-click rollback, and degrade-to-rules when calibration drifts-aim to convert combination experimentation into an auditable, risk-minimizing bedside layer. This review synthesizes the rationale for micro-dosed, order-aware adjuncts, summarizes implementable class-level candidates using approved agents and routine assays (with investigational items restricted to protocol settings), and outlines an evaluation plan embedded in care that prioritizes feasibility, safety, and mechanistic informativeness while protecting SoC delivery.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"4461-4468"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147693434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Morphological and molecular characterization of epithelial ovarian cancer: SEOM-SEAP consensus guidelines for biomarker integration in clinical practice.","authors":"Gabriel Matheu, María José Bermejo-Peréz, Nuria Escudero-García, Carmen Garcia-Duran, Sonia Gatius-Caldero, Eva Guerra-Alía, Susana López-Agullo, Ignacio Romero, Geanella Yange, Maria-Pilar Barretina-Ginesta","doi":"10.1007/s12094-026-04335-3","DOIUrl":"10.1007/s12094-026-04335-3","url":null,"abstract":"<p><p>Epithelial ovarian cancer (OC) is the second leading cause of death among gynecologic malignancies and exhibits marked histological and molecular heterogeneity. Advances in tumor biology and targeted therapies have increased the need for accurate biomarker characterization. This updated consensus by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP) reviews key morphological and molecular features for diagnosis and providing recommendations for biomarker assessment across major OC subtypes. The document addresses classical serum biomarkers, prognostic tools, and genomic alterations with therapeutic implications, including homologous recombination deficiency (HRD), BRCA1 and BRCA2 mutations, mismatch repair status, as well as other established and emerging biomarkers. Emphasis is placed on optimal sample selection, validated techniques, and multidisciplinary integration is required to ensure diagnostic quality. These recommendations aim to optimize prognostic stratification and guide personalized treatment strategies, ultimately improving clinical outcomes in ovarian cancer.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"4359-4375"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13601113/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147876598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early access to medicines in Spain: a retrospective hospital study with a proposal for a regulatory change.","authors":"Jose Porcel-Maleno, Gerard Ronda-Roca, Arantxa Sancho-López, Mónica Lobo-Palomar, Lourdes Gutierrez-Sanz, Gustavo Adolfo Centeno-Soto, Cristina Avendaño-Solá, Concepcion Payares-Herrera","doi":"10.1007/s12094-026-04349-x","DOIUrl":"10.1007/s12094-026-04349-x","url":null,"abstract":"<p><strong>Background: </strong>Medicines awaiting price and reimbursement (P&R) decisions represent a delicate situation in the Spanish NHS. The interval between marketing authorisation (MA) and PR averages 616 days, leaving patients without standard access to EU-approved treatments for almost 2 years, despite their eventual availability. While early access before MA is regulated, no framework exists for the period between MA and PR. Responsibility for funding falls to hospitals or autonomous regions, with no harmonised criteria, leading to inequities in access.</p><p><strong>Objectives: </strong>To describe our access model to medicines in special situations (MSS), and to evaluate the clinical and regulatory implications of this procedure.</p><p><strong>Methods: </strong>We conducted a 2-year retrospective review of MSS access requests. Our tertiary hospital uses a transparent pathway: clinicians submit a consultation to Clinical Pharmacology and Hospital Pharmacy; departments issue independent reports to Hospital Administration, which decides, considering individual justification, clinical need, early access, and treatment benefit.</p><p><strong>Results: </strong>A total of 295 request were received, and 78 involved products pending PR decision. Of them, 73 (93.6%) were granted local access. Subsequently, PR status changed to regular access in 64.1% of these requests (50/78), ensuring early access for 62.8% of patients (49/78). Onco-haematological patients granted early access showed an overall disease control rate of 63%, with a median survival of 16 months.</p><p><strong>Conclusions: </strong>Until legislation regulates access to medicines awaiting reimbursement, or decision times are reduced, implementing robust local procedures is essential to guarantee fair and equitable MSS access, particularly for patients requiring treatment before national PR resolution.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"4903-4914"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13601080/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147730490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and prognostic factors in pleural mesothelioma: insights from a Latin American cohort.","authors":"Ricardo Brugés, Carlos Carvajal, Marcela Núñez, Alejandra Navarrete, Rafael Parra-Medina","doi":"10.1007/s12094-026-04337-1","DOIUrl":"10.1007/s12094-026-04337-1","url":null,"abstract":"<p><strong>Background: </strong>Pleural mesothelioma (PM) remains a lethal but preventable disease whose burden is shifting toward low- and middle-income countries (LMICs) where asbestos use has persisted or has only recently been banned. This study describes the clinical characteristics, management patterns, and prognostic factors of PM in a contemporary Colombian cohort.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of adults with histologically confirmed pleural mesothelioma diagnosed at a tertiary referral cancer center in Bogotá, Colombia, from January 1, 2011, to December 31, 2023. Overall survival (OS) was defined from the histologic diagnosis date to death from any cause; patients without a recorded death were censored at the last documented oncologic contact. Real-world progression-free survival (PFS) was defined from diagnosis to documented progression (radiologic or clinician-documented) or death, whichever occurred first; patients without progression or death were censored at last contact. Survival was estimated using Kaplan-Meier methods and modeled using Cox proportional hazards regression.</p><p><strong>Results: </strong>The cohort included 106 patients (mean age, 63.2 years; 73.6% male; 84.9% epithelioid histology). There were 105 deaths (1 OS censor). Median OS was 9.9 months (95% CI, 7.1-14.1), with 12- and 24 month OS of 46.2% and 12.3%. Real-world PFS included 105 events (1 PFS censor). Median PFS was 8.1 months (95% CI, 6.2-9.4), with 12- and 24 month PFS of 30.2% and 6.6%. In multivariable analyses focused on baseline prognostic factors, ECOG performance status 2-3 was associated with shorter OS and PFS.</p><p><strong>Conclusions: </strong>In this contemporary Colombian cohort, OS and PFS were short, and baseline functional status was strongly associated with outcomes. Treatment-stratified survival patterns are reported descriptively and should not be interpreted as comparative effectiveness. These data add regional evidence for pleural mesothelioma prognosis in routine practice.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"4839-4848"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13601149/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147823205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Head and neck squamous cell carcinoma: current and emerging therapeutic strategies.","authors":"Parul Ahuja, Lokesh Kadian, Sandeep Goyal, Ritu Yadav","doi":"10.1007/s12094-026-04385-7","DOIUrl":"10.1007/s12094-026-04385-7","url":null,"abstract":"<p><p>Head and neck squamous cell carcinoma (HNSCC) is a complex, aggressive and heterogeneous malignancy with trends rising rapidly worldwide. Tobacco use, alcohol consumption and human papillomavirus (HPV) infection are the leading risk factors associated with the occurrence of HNSCC. Standard treatments, including radiotherapy, chemotherapy, and surgical resection, are often associated with severe side effects and limited success, particularly in advanced, recurrent, or metastatic disease. Though the introduction of immune checkpoint inhibitors has reshaped the management of recurrent or metastatic disease, the clinical impact remains limited as a majority of patients do not achieve expected prognosis, attributed to a \"cold\" tumor microenvironment. Therefore, to enhance the clinical outcomes of HNSCC patients, it is priority to investigate more effective and well-tolerated targeted medicines. This review provides insights about the current treatment strategies, challenges associated with these traditional approaches along with shedding light on the state-of-the-art HNSCC treatment modalities such as advanced surgery, immunotherapy, epigenetics and cancer stem cell targeting, etc. Moreover, therapies involving varied sophisticated combinations of the abovementioned conventional approaches and these advanced treatment modalities have yielded better HNSCC prognosis in multiple preclinical and clinical settings. Continued multidisciplinary research targeting molecular pathways and innovative drug delivery systems hold the potential to remarkably enhance treatment efficacy while preserving patient's quality of life.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"4389-4418"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147950072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tozasertib + cisplatin inhibits proliferation, migration, and induces apoptosis in esophageal carcinoma cells.","authors":"Chunqin Tian, Lichun Cui, Xiaoyan Wang","doi":"10.1007/s12094-026-04358-w","DOIUrl":"10.1007/s12094-026-04358-w","url":null,"abstract":"<p><strong>Background: </strong>Esophageal cancer is a highly aggressive malignancy with limited treatment options. Cisplatin (CDDP)-based chemotherapy is often restricted by the development of drug resistance and systemic toxicity. Aurora kinase inhibitors have emerged as promising chemosensitizers in various cancers.</p><p><strong>Objective: </strong>It was to investigate the impact of the kinase inhibitor Tozasertib (VX-680) on the extracellular signal-regulated kinase (ERK) pathway and its synergistic mechanism with cisplatin (CDDP) in inducing senescence in esophageal cancer cells.</p><p><strong>Methods: </strong>Experiments were conducted using human esophageal cancer cell lines TE-1 and KYSE150, with the following groups: blank control, Tozasertib monotherapy, CDDP monotherapy, Tozasertib combined with CDDP, and a positive control group of CDDP + 5-fluorouracil (5-FU) (3 μM CDDP + 30 μM 5-fluorouracil). Cell proliferation, migration, and apoptosis, and protein levels of all groups were compared and analyzed.</p><p><strong>Results: </strong>Tozasertib + CDDP group (0.08 μM Tozasertib + 0.75 μg/mL CDDP) demonstrated significantly reduced cell proliferation rates (41.6% ± 2.9% in TE-1 cells and 38.2% ± 3.1% in KYSE150 cells) and migration rates (7.3% ± 1.8% in TE-1 and 8.5% ± 1.4% in KYSE150), with superior efficacy compared to monotherapy groups (P < 0.05). The Tozasertib + CDDP group exhibited the highest apoptosis rate at 48 h (TE-1: 44.6% ± 4.5%; KYSE150: 42.3% ± 4.4%, P < 0.05). Conditioned medium from the Tozasertib + CDDP group showed the strongest inhibitory effect on human umbilical vein endothelial cell (HUVEC) tube formation (total tube length: 3220 ± 401 pixels for TE-1-derived and 3390 ± 388 pixels for KYSE150-derived, P < 0.01). Western blot analysis revealed significant upregulation of cleaved PARP and cleaved caspase-3 (P < 0.05), along with marked downregulation of pro-caspase-3, phosphorylated ERK (p-ERK), matrix metalloproteinase-2 (MMP-2), vascular endothelial growth factor (VEGF), Cyclin B1, and c-Myc expression (P < 0.05) in the Tozasertib + CDDP group.</p><p><strong>Conclusion: </strong>In summary, aurora kinase inhibitor combined with CDDP could suppress the ERK pathway to affect the biological process of esophageal carcinoma cells. Versus a simple drug, a drug combination could effectively inhibit the proliferation and migration of esophageal carcinoma cells, promote apoptosis, reduce angiogenesis, and induce cell cycle arrest.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"4714-4727"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147788088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Androgen receptor pathway inhibitor intensification in non-metastatic hormone-sensitive prostate cancer: current evidence and clinical implications.","authors":"Patricia Willisch, Beatriz Vázquez-Barreiro, Ana Plata, Irene Cienfuegos Belmonte, Gloria Guardia, Rocío Del Castillo-Acuña, Giulio Francolini, Ciro Franzese, José Daniel Subiela Henríquez, Felipe Couñago, Fernando López-Campos","doi":"10.1007/s12094-026-04350-4","DOIUrl":"10.1007/s12094-026-04350-4","url":null,"abstract":"<p><p>Prostate cancer is the most common malignancy in men. Although frequently diagnosed at localized stages, a substantial proportion present high-risk features associated with biochemical recurrence and progression. In non-metastatic hormone-sensitive prostate cancer (nmHSPC), standard treatment has traditionally consisted of local therapy combined with androgen deprivation therapy (ADT), but recent advances have reshaped the therapeutic landscape. The addition of androgen receptor pathway inhibitors (ARPIs) to ADT has demonstrated substantial survival benefits in metastatic hormone-sensitive disease, providing the rationale for exploring treatment intensification in earlier stages. Modern imaging techniques, particularly PSMA PET, enable detection of occult metastatic disease influencing treatment selection. Emerging evidence from randomized and phase II-III studies suggests that ARPI intensification combined with radiotherapy, surgery, or salvage approaches may improve disease control in selected high-risk nmHSPC populations. This narrative review summarizes the evidence supporting ARPI intensification in nmHSPC and discusses the clinical implications of recent advances.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"4376-4388"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147655416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of radiotherapy on quality of life reported by elderly patients.","authors":"Pilar MªSamper Ots, Carolina de la Pinta, Dolores de Las Peñas Cabrera, Miriam Palomas Moreno, Lucia Tueros Farfán, Lidia Gómez Perea, Carla Sánchez Cortés, Andrea Bobo Jaureguizar, José Luis Monroy Antón","doi":"10.1007/s12094-026-04298-5","DOIUrl":"10.1007/s12094-026-04298-5","url":null,"abstract":"<p><strong>Objectives and purposes: </strong>To determine the impact of radical radiotherapy (RT) treatment on the quality of life reported by elderly patients.</p><p><strong>Materials and methods: </strong>A prospective multicenter study was conducted in 8 national centers. Patients over 70 years old who had an indication for radical RT were included. All patients were initially assessed with the Geriatric-8 (G8) scale, ECOG PS, Nutriscore, SARC_F (sarcopenia questionnaire), and completed two patient-reported outcomes measure (PROMs) questionnaires: the EORTC_QLQ_C30 and the EORTC_ELD_14 quality of life (QoL), at baseline, at the end of RT, and 3 months later.</p><p><strong>Results: </strong>A total of 156 patients with a mean age of 77 years (range 70-93) were included. The characteristics of the patients are as follows: 65.4% are men, 45.5% have prostate cancer, 20% breast cancer, and 12.2% lung cancer. The baseline PROMs show general health status of patients >70 years with some deterioration (73.5 ± 20.3). Patients also present deterioration in physical function (85.29 ± 19.94), emotional function (81.02 ± 21.28), and maintenance of purpose (70.94 ± 30.5), and the most frequent baseline symptoms are constipation, fatigue, insomnia, worries about others, future worries, disease burden, and joint stiffness. The prognostic factors that increase the risk of these alterations are ECOG PS >1, female sex, diabetes, dyslipidemia, pulmonary pathology, cognitive impairment, and especially the risk of sarcopenia. When comparing PROMs at the beginning and at the end of oncological treatment, a significant deterioration in role function (89.86 vs. 85.62, p = 0.004) and an increase in fatigue (19.89 vs. 25.78, p = 0.002) are observed. While the PROMs at 3 months show improvement in all functions and symptoms, statistically significant improvement was only found in emotional function (84 vs. 89.26, p = 0.000), fatigue (25.87 vs. 20.4, p = 0.001), loss of appetite (12.75 vs. 6.7, p = 0.003), and maintenance of purpose (68 vs. 73.6, p = 0.14).</p><p><strong>Conclusion: </strong>Older patients, due to their comorbidities, already have alterations in QoL, with sarcopenia being an important factor. Cancer treatment further deteriorates QoL in a significant way, role function and fatigue, but 3 months after the treatment, improvements in QoL, significantly emotional function, fatigue, loss of appetite and maintenance of purpose are observed.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"4927-4936"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147823247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}